Norbinaltorphimine
Chemical compound
From Wikipedia, the free encyclopedia
Norbinaltorphimine (nor-BNI or nBNI) is an opioid receptor antagonist used in scientific research. It is a highly selective inverse agonist for the κ-opioid receptor.[1][2] In animals, nor-BNI blocks the effects of κ-opioids[3][4] with a slow onset and an exceptionally long duration of action (up to several months).[5][6] It produces antidepressant-like[7] and anxiolytic-like effects in animal models.[8]
- none
- US: Schedule II (derivative of noroxymorphone)
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C40H43N3O6 |
| Molar mass | 661.799 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Legality
In the United States, a letter from Terrence L. Boos, Ph.D., Chief Drug & Chemical Evaluation Section Diversion Control Division at the DEA shows they consider nor-BNI a Schedule II substance as a derivative of noroxymorphone due to its broad definition in the CSA covering "derivatives". However, no court cases are known to exist for its prosecution and it is possible this could be challenged in court.[9]